Quinazoline derivatives and pharmaceutical compositions...

Details Quinazoline derivatives and pharmaceutical compositions... Quinazoline derivatives and pharmaceutical compositions...

2005-05-24

2005-05-24

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S266400, C514S266400, C514S231500, C514S228200, C544S283000, C544S284000, C544S293000, C544S106000, C544S056000, C544S059000, C544S062000

Reexamination Certificate

active

06897210

ABSTRACT:
The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6(wherein R5and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10and R11each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compostions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGP, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

REFERENCES:
patent: 3266990 (1966-08-01), Lutz et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 5373011 (1994-12-01), Haley
patent: 5409930 (1995-04-01), Spada et al.
patent: 5411963 (1995-05-01), Dreikorn et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5480883 (1996-01-01), Spada et al.
patent: 5569658 (1996-10-01), Barker
patent: 5571815 (1996-11-01), Schaper et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5616582 (1997-04-01), Barker
patent: 5646153 (1997-07-01), Spada et al.
patent: 5650415 (1997-07-01), Tang et al.
patent: 5656643 (1997-08-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5736534 (1998-04-01), Arnold
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5770603 (1998-06-01), Gibson
patent: 5792771 (1998-08-01), App et al.
patent: 5814630 (1998-09-01), Barker et al.
patent: 5821246 (1998-10-01), Brown et al.
patent: 5866572 (1999-02-01), Barker et al.
patent: 5929080 (1999-07-01), Frost
patent: 5932574 (1999-08-01), Baker
patent: 5942514 (1999-08-01), Barker
patent: 5952333 (1999-09-01), Barker
patent: 5955464 (1999-09-01), Barker
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6015814 (2000-01-01), Barker
patent: 6057320 (2000-05-01), Spada et al.
patent: 6071921 (2000-06-01), Lohmann et al.
patent: 6184225 (2001-02-01), Thomas et al.
patent: 02213558 (1972-10-01), None
patent: 19614718 (1997-10-01), None
patent: 0 326 307 (1989-02-01), None
patent: 0 326 330 (1989-08-01), None
patent: 0 520 722 (1992-12-01), None
patent: 0 566 226 (1993-10-01), None
patent: 0 602 851 (1994-06-01), None
patent: 0 635 498 (1995-01-01), None
patent: 0 635 507 (1995-01-01), None
patent: 0 743 308 (1996-11-01), None
patent: 0 787 722 (1997-08-01), None
patent: 0 837 063 (1998-04-01), None
patent: 2 033 894 (1980-05-01), None
patent: 2 160 201 (1985-12-01), None
patent: 54-2327 (1979-09-01), None
patent: WO 8704321 (1987-07-01), None
patent: WO 9214716 (1992-09-01), None
patent: WO 9216527 (1992-10-01), None
patent: WO 9220642 (1992-11-01), None
patent: WO 9515758 (1995-06-01), None
patent: WO 9519169 (1995-07-01), None
patent: WO 9521613 (1995-08-01), None
patent: WO 9523141 (1995-08-01), None
patent: WO 9524190 (1995-09-01), None
patent: WO 9609294 (1996-03-01), None
patent: WO 9615118 (1996-05-01), None
patent: WO 9616960 (1996-06-01), None
patent: WO 9629331 (1996-09-01), None
patent: WO 9630347 (1996-10-01), None
patent: WO 9630370 (1996-10-01), None
patent: WO 9633977 (1996-10-01), None
patent: WO 9633978 (1996-10-01), None
patent: WO 9633979 (1996-10-01), None
patent: WO 9633980 (1996-10-01), None
patent: WO 9633981 (1996-10-01), None
patent: WO 9639145 (1996-12-01), None
patent: WO 9640648 (1996-12-01), None
patent: WO 9640673 (1996-12-01), None
patent: WO 9702266 (1997-01-01), None
patent: WO 9703069 (1997-01-01), None
patent: WO 9717329 (1997-05-01), None
patent: WO 9722596 (1997-06-01), None
patent: WO 9728161 (1997-08-01), None
patent: WO 9730034 (1997-08-01), None
patent: WO 9730035 (1997-08-01), None
patent: WO 9730044 (1997-08-01), None
patent: 9732856 (1997-09-01), None
patent: WO 9734876 (1997-09-01), None
patent: WO 9737999 (1997-10-01), None
patent: WO 9738983 (1997-10-01), None
patent: WO 9738994 (1997-10-01), None
patent: WO 9742187 (1997-11-01), None
patent: WO 9749689 (1997-12-01), None
patent: WO 9802434 (1998-01-01), None
patent: WO 9810767 (1998-03-01), None
patent: WO 9813350 (1998-04-01), None
patent: WO 9814431 (1998-04-01), None
patent: WO 9823613 (1998-06-01), None
patent: WO 9835958 (1998-08-01), None
patent: WO 9843960 (1998-10-01), None
patent: WO 9850038 (1998-11-01), None
patent: WO 9906378 (1999-02-01), None
patent: WO 9906396 (1999-02-01), None
patent: WO 9909016 (1999-02-01), None
patent: WO 9909024 (1999-02-01), None
patent: WO 9910349 (1999-03-01), None
US RE36,265, 8/1999, Spada et al. (withdrawn)
Rewcastle et al,J. Med. Chem. 38/18,3482-7(1995).*
Chemical Abstract DN :132:160709, also cited as Klohs et al, Currt. Opinion. Biotechnol. 10/6,544-49(1999).*
Arya et al., Nitroimidazoles: Part XVI—Some 1-Methyl-4-nitro-5-substituted Imidazoles, Indian Journal of Chemistry, vol. 21B, Dec. 1982, pp. 1115-1117.
Bridges, “The current status of tyrosine kinase inhibitors . . . ,” Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776.
Bridges, et al., “Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(a-Phenethylamino)quinazolines,” Bioorganic & Medicinal Chemistry, vol. 3, No. 12, pp. 1651-1656, 1995.
Connolly, et al., “Human Vascular Permeability Factor,” J.Bio.Chem., vol. 264, No. 33, Nov. 1989, pp. 20017-20024.
Cullinan-Bove, et al., “Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus . . . ,” Endocrinology, vol. 133, No. 2, 1993, pp. 829-837.
Fan, et al., “Controlling the Vasculature: Angiogenesis, Anti-Angiogenesis . . . ,” TiPS Review, vol. 16, Feb. 1995, pp. 57-65.
Folkman, “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease,” Nature Medicine, vol. 1, No. 1, 1995, pp. 27-30.
Fry et al., “A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase,” SCIENCE, vol. 265, Aug. 19, 1994, pp. 1093-1095.
Gazit et al., Tyrophostins IV-Highly Potent Inhibitors . . . Relationship Study of 4-Anilidoquinazolines, Bioorganic & Medicinal Chemistry, vol. 4. No. 8, 1996, pp. 1203-1207.
Golovkin et al., Nauchin TR-VSES-NAUCHNO-ISSLED INST FARM, 1990, 28, 70-75.
Klohs et al., “Antiangiognenic Agents”, Curr. Opin. Biotech, 1/6, 1999, 544-549 (Abstract Attached).
Higashino et al., “Reactions of the Anion of Quinazoline Reissert Compound (3-Benzoyl-3,4-dihydro-4-quinazolinecarbonitrile) with Electrophiles”, Chem. Phar. Bull. 33(3), 1985, pp. 950-961.
Hara et al., On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1), J. Heterocyclic Chem. vol. 19, 1982, pp. 1285-1287.
Iyer, et al., “Studies in Potential Amoebicides: Part III-Synthesis of 4-Substituted Amino-8-Hydroxy) Quina

Affiliated with

Also associated with

Rating

Quinazoline derivatives and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives and pharmaceutical compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3424659